CALT News and Press, Calliditas Therapeutics AB From 05/14/24

2024-05-14 08:01:12 ET More on Calliditas Therapeutics Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript Calliditas releases phase 2 results on head and neck cancer asset setanaxib Seeking Alpha’s Quant Rating on Calliditas Therapeutics...

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China PR Newswire STOCKHOLM , May 14, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announces that its partner ...

2024-05-06 11:52:08 ET More on Calliditas Therapeutics Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Calliditas Therapeutics Historical earnings data for Calliditas Therapeutics Financial info...

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib PR Newswire STOCKHOLM , May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Callid...

2024-04-30 00:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Calliditas Therapeutics' 2023 Annual Report Published PR Newswire STOCKHOLM , April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM : CALTX ) ("Calliditas") today announces that the Annual Report for 2023 now is...

Calliditas Announces Positive NefIgArd Open Label Extension Results PR Newswire STOCKHOLM , April 24, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM : CALTX) ("Calliditas") today announced that the global open-label ex...

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 PR Newswire STOCKHOLM , April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nas...

2024-04-11 15:23:48 ET Summary Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. Povetacicept has shown promising results in reducing protei...

2024-04-10 07:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...